Published 1 day ago • loading... • Updated 12 hours ago

RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation

RiboX Therapeutics has begun dosing the first patient in its Phase I/IIa clinical trial for RXRG001, targeting radiation-induced xerostomia and hyposalivation.
RiboX Therapeutics announced that the first patient was dosed in its Phase I/IIa clinical trial for RXRG001, aiming to treat radiation-induced xerostomia and hyposalivation.

Insights by Ground AI

Does this summary seem wrong?

43 Articles

All

Left

Center

Right

Buffalo News

+40 Reposted by 40 other sources

RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation

PRINCETON, N.J., March 9, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH) Phase…

18 hours ago·Buffalo, United States

Read Full Article

pipelinereview

RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation - Pipelinereview

PRINCETON, NJ, USA I March 9, 2025 I RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH) Phase I/IIa clinical trial (SPRINX-1) evaluating the safety and efficacy of RXRG001 in patients with radiation-induced-xerostomia (RIX) and hyposalivation. Xerostomia and…

12 hours ago

Read Full Article

csimarket.com

#Tenax Therapeutics Expands Phase 3 LEVEL Program Amid Financial Challenges

Tenax Therapeutics, a biopharmaceutical company focused on developing innovative therapies for pulmonary hypertension and heart failure, has announced the expansion of its Phase 3 LEVEL program. This initiative includes the progression of two TNX-103 (Oral Levosimendan) registrational studies for treating pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). While the company is advancing its clinical …

1 day ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year